Hi @Richard.W , not directly related to the topic, but what are your thoughts on VTRS?
I know you received it as a spin-off from Pfizer, but why did you decide to hold it as opposed to selling it?
It seems to have a lot of debt and declining revenues (unsure about the pipeline), so I am curious to see what other people’s thoughts are on it 
.
I have only a tiny position in VTRS, just 0.03% of my portfolio. So I have not given it much thought. I notice mean analyst price target is $20. Currently $14. May as well stick with it to see if analysts are right. Small loss if they are wrong.
2 Likes
How coincidental. VTRS up over 7% and leading healthcare sector today.
1 Like